Letters, Testimony & Comments

The Biotechnology Innovation Organization (BIO) submits these comments in response to the U.S. Environmental Protection Agency’s (EPA) request for public input on the receipt of an application, 93167-EUP-2, from Oxitec Ltd requesting to amend and…

The undersigned organizations write to encourage policymakers to remove provisions in the Build Back Better Act that would curtail the effectiveness of Qualified Small Business Stock (QSBS) in incentivizing investment in innovative small businesses…

To meet the challenge of climate change, it is crucial to lead with science and U.S. innovation. We must incentivize the adoption of innovative, sustainable technologies and practices; and streamline and expedite regulatory pathways for breakthrough…

Safe, secure, affordable & accessible food supply Hundreds of millions of Americans and people around the world rely on safe and nutritious U.S. agricultural products and foods. Americans have access to one of the safest, most diverse, most…

The undersigned organizations and institutions, representing hundreds of thousands of individuals and entities working in science, technology, engineering, medicine, and mathematics would like to call your attention to the recent reintroduction of…

We want to commend you and your Administration for the global distribution of millions of doses of the COVID-19 vaccines. Our friends in recipient countries are truly grateful. Nonetheless, in order to gain control of the pandemic, a much more…

On Thursday, June 10th, 2021, the U.S. Food and Drug Administration (FDA) published a draft guidance, Core Patient-Reported Clinical Outcomes in Cancer Clinical Trials, providing recommendations to sponsors on the collection of a core set of patient…

BIO submitted comments to the United States Patent and Trademark Office in response to the USPTO's consideration of “the codification of its current policies and practices, or the modification thereof,” relating to the exercise of its discretion…

BIO regularly publishes reports that help us assess the health of the biopharmaceutical pipeline across different diseases so that we can identify and remove barriers to providing next generation cures and treatments to patients and their families…

COVID-19 will not be our last public health emergency.  We face numerous bio-threats from natural and bioterror threats.  Strong support for medical countermeasures R&D is critical to protecting our national security. Today I will…